Tenaya Therapeutics Inc (TNYA)
4.65
+0.40
(+9.41%)
USD |
NASDAQ |
May 17, 16:00
4.65
0.00 (0.00%)
After-Hours: 20:00
Tenaya Therapeutics Enterprise Value: 243.64M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 243.64M |
| May 16, 2024 | 211.45M |
| May 15, 2024 | 211.45M |
| May 14, 2024 | 223.23M |
| May 13, 2024 | 213.81M |
| May 10, 2024 | 207.52M |
| May 09, 2024 | 229.51M |
| May 08, 2024 | 231.86M |
| May 07, 2024 | 239.72M |
| May 06, 2024 | 234.22M |
| May 03, 2024 | 245.21M |
| May 02, 2024 | 240.50M |
| May 01, 2024 | 245.21M |
| April 30, 2024 | 234.22M |
| April 29, 2024 | 234.22M |
| April 26, 2024 | 216.16M |
| April 25, 2024 | 209.09M |
| April 24, 2024 | 221.66M |
| April 23, 2024 | 227.15M |
| April 22, 2024 | 225.58M |
| April 19, 2024 | 216.95M |
| April 18, 2024 | 214.59M |
| April 17, 2024 | 215.38M |
| April 16, 2024 | 227.94M |
| April 15, 2024 | 228.72M |
| Date | Value |
|---|---|
| April 12, 2024 | 227.94M |
| April 11, 2024 | 246.00M |
| April 10, 2024 | 229.51M |
| April 09, 2024 | 233.44M |
| April 08, 2024 | 241.29M |
| April 05, 2024 | 246.00M |
| April 04, 2024 | 237.36M |
| April 03, 2024 | 253.85M |
| April 02, 2024 | 238.15M |
| April 01, 2024 | 269.55M |
| March 28, 2024 | 306.00M |
| March 27, 2024 | 300.50M |
| March 26, 2024 | 274.59M |
| March 25, 2024 | 276.95M |
| March 22, 2024 | 265.95M |
| March 21, 2024 | 270.66M |
| March 20, 2024 | 280.09M |
| March 19, 2024 | 251.04M |
| March 18, 2024 | 273.81M |
| March 15, 2024 | 285.98M |
| March 14, 2024 | 269.88M |
| March 13, 2024 | 320.13M |
| March 12, 2024 | 331.12M |
| March 11, 2024 | 328.77M |
| March 08, 2024 | 397.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-74.15M
Minimum
Nov 08 2022
984.50M
Maximum
Aug 27 2021
206.40M
Average
153.21M
Median
Aug 07 2023
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 14.77B |
| Corvus Pharmaceuticals Inc | 121.11M |
| Solid Biosciences Inc | 137.43M |
| Dyne Therapeutics Inc | 1.965B |
| Sana Biotechnology Inc | 1.623B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.23M |
| Total Expenses (Quarterly) | 33.76M |
| EPS Diluted (Quarterly) | -0.40 |
| Earnings Yield | -35.19% |